|
AdPEDF
|
DB05138 |
[AdPEDF is under development for the treatment of wet age-related macular degeneration (AMD). It has been shown to rapidly elevate the intraocular AdPEDF protein levels in the eye, inhibit abnormal blood vessel growth, and cause abnormal blood vessels to regress while protecting the eye’s photoreceptors.] |
|
Lestaurtinib
|
DB06469 |
|
|
5-(2-PHENYLPYRAZOLO[1,5-A]PYRIDIN-3-YL)-1H-PYRAZOLO[3,4-C]PYRIDAZIN-3-AMINE
|
DB07794 |
|
|
Lobeline
|
DB05137 |
[An alkaloid that has actions similar to nicotine on nicotinic cholinergic receptors but is less potent. It has been proposed for a variety of therapeutic uses including in respiratory disorders, peripheral vascular disorders, insomnia, and smoking cessation. [PubChem]] |
|
Cariporide
|
DB06468 |
|
|
Fisetin
|
DB07795 |
|
|
Bavituximab
|
DB05136 |
[Bavituximab is a chimeric Anti-PS monoclonal antibody analog which is used to potentially treat cancers and viral infections. It binds to phosphatidylserine and other exposed host cell lipids when induced by cellular stress. Additional analogs in the class include 3G4, 2aG4, 9d2 and Hu3g4.] |
|
Apolizumab
|
DB06467 |
[Apolizumab is a humanized monoclonal antibody that is being studied as a treatment for hematologic cancers.] |
|
Vibriolysin
|
DB05135 |
[Vibriolysin is a proteolytic enzyme secreted by the marine microorganism Vibrio proteolyticus. It is a new agent for enzymatic debridement, shown to rapidly and thoroughly hydrolyze burn wound eschar within full-thickness wounds.] |
|
(3ASR,4RS,8ASR,8BRS)-4-(2-(4-FLUOROBENZYL)-1,3-DIOXODEACAHYDROPYRROLO[3,4-A] PYRROLIZIN-4-YL)BENZAMIDINE
|
DB07796 |
|
|
Matuzumab
|
DB05101 |
[Matuzumab (formerly known as the experimental drug, EMD 72000) is a humanized monoclonal antibody used in cancer treatment. It has a high affinity for EGFR (epithelial growth factor receptor), frequently associated with the growth of blood vessels in malignancy, facilitating tumor growth and survival.] |
|
FLUORESCIN
|
DB07764 |
|
|
METHYL 1-(4-{[(2,4-DIAMINOPTERIDIN-6-YL)METHYL](METHYL)AMINO}BENZOYL)PIPERIDINE-4-CARBOXYLATE
|
DB07765 |
|
|
Prinomastat
|
DB05100 |
[Prinomastat is a synthetic hydroxamic acid derivative with potential antineoplastic activity. Prinomastat inhibits matrix metalloproteinases (MMPs) (specifically, MMP-2, 9, 13, and 14), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis. As a lipophilic agent, prinomastat crosses the blood-brain barrier. ] |
|
Evernimicin
|
DB06431 |
|
|
(2Z,3E)-2,3'-biindole-2',3(1H,1'H)-dione 3-{O-[(3R)-3,4-dihydroxybutyl]oxime}
|
DB07766 |
|
|
Ferulic acid
|
DB07767 |
|
|
Epitestosterone
|
DB07768 |
[Epitestosterone is the 17-alpha isomer of testosterone, derived from pregnenolone via the delta5-steroid pathway, and via 5-androstene-3-beta,17-alpha-diol. Epitestosterone acts as an antiandrogen in various target tissues. The ratio between testosterone/epitestosterone is used to monitor anabolic drug abuse.] |
|
S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
|
DB07769 |
|
|
Trabectedin
|
DB05109 |
[Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.] |
